FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Agency Reference Model Suggested for Next Level Preemption

A law journal article, discussed in Regulatory Review, proposes a framework courts could use to consider state challenges to federal preemption of dru...

latest-news-card-1
Medical Devices

3 Former Magellan Execs Sentenced

The Department of Justice says a Massachusetts federal judge sentenced three former Magellan Diagnostics executives for hiding a malfunction in the co...

latest-news-card-1
Human Drugs

Quality System Violations at Hong Qiangxing Electronics

FDA warns Chinas Hong Qiangxing Shenzhen Electronics about Quality System violations in its production of several medical devices.

latest-news-card-1
Human Drugs

Owen Biosciences CGMP Violations

FDA warns Baton Rouge, LA-based Owen Biosciences about CGMP violations in its production of finished drugs as a contract manufacturing facility.

latest-news-card-1
Biologics

Gene Therapy for Broader Spinal Muscular Atrophy Range

FDA approves Novartis Itvisma (onasemnogene abeparvovec-brve), a new formulation of a gene therapy for a broader age of spinal muscular atrophy patien...

latest-news-card-1

Guidance on Where to Submit Cross-Center Master Files

FDA issues a draft guidance with recommendations to help master file holders determine to which Center to submit cross-Center master files.

latest-news-card-1

Makary Missing the Point on Advisory Committees: Zuckerman

National Center for Health Research president Diana Zuckerman defends FDA advisory committees, saying they do a more thorough job of evaluating produc...

latest-news-card-1
Human Drugs

Amycretin Sees 14.5% Weight Loss in Phase 2 Diabetes Trial

Novo Nordisk reports favorable Phase 2 data for its investigational dual-action obesity and diabetes drug amycretin, showing significant reductions in...

latest-news-card-1
FDA General

Study Finds Public Speaker Conflicts at FDA Panel Meetings

A new study of FDA advisory committee meetings reveals that a substantial portion of public speakers support drug approval, and many have financial co...

latest-news-card-1
Human Drugs

Catalent Indiana FDA-483 Has Six Observations

FDA releases the form FDA-483 with six observations from an inspection at the Catalent Indiana sterile drug manufacturing facility in Bloomington, IN.